As pain is such a heterogeneous indication, significant opportunities remain for a variety of different and more effective non-opioid treatment options to be developed.

Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal hemoglobinuria Initial results for odronextamab in first ...

Most people approach problems with a single lens, viewing market fluctuation through a strictly economic filter or a ...

Additional oral presentations explore odronextamab in areas of high unmet need, including the primary analysis in diffuse large B-cell lymphoma progressing after CAR-T therapy and first results in ...